These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20489052)

  • 1. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.
    Alchalby H; Badbaran A; Zabelina T; Kobbe G; Hahn J; Wolff D; Bornhäuser M; Thiede C; Baurmann H; Bethge W; Hildebrandt Y; Bacher U; Fehse B; Zander AR; Kröger N
    Blood; 2010 Nov; 116(18):3572-81. PubMed ID: 20489052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
    Lestang E; Peterlin P; Le Bris Y; Dubruille V; Delaunay J; Godon C; Theisen O; Blin N; Mahe B; Gastinne T; Garnier A; Touzeau C; Voldoire M; Bene MC; Le Gouill S; Milpied N; Mohty M; Moreau P; Guillaume T; Chevallier P
    Eur J Haematol; 2017 Jul; 99(1):60-69. PubMed ID: 28370306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.
    Guglielmelli P; Barosi G; Specchia G; Rambaldi A; Lo Coco F; Antonioli E; Pieri L; Pancrazzi A; Ponziani V; Delaini F; Longo G; Ammatuna E; Liso V; Bosi A; Barbui T; Vannucchi AM
    Blood; 2009 Aug; 114(8):1477-83. PubMed ID: 19549988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.
    Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Rosillo C; Camoriano JK
    Am J Hematol; 2007 May; 82(5):400-2. PubMed ID: 17133423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes.
    Rafati M; Brown DW; Zhou W; Jones K; Luo W; St Martin A; Wang Y; He M; Spellman SR; Wang T; Deeg HJ; Gupta V; Lee SJ; Bolon YT; Chanock SJ; Machiela MJ; Saber W; Gadalla SM
    Blood Adv; 2023 Dec; 7(24):7506-7515. PubMed ID: 38011490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.
    Alchalby H; Yunus DR; Zabelina T; Kobbe G; Holler E; Bornhäuser M; Schwerdtfeger R; Bethge W; Kvasnicka HM; Büsche G; Ayuk F; Bacher U; Zander AR; Kröger N
    Br J Haematol; 2012 Apr; 157(1):75-85. PubMed ID: 22280409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.
    Kröger N; Badbaran A; Holler E; Hahn J; Kobbe G; Bornhäuser M; Reiter A; Zabelina T; Zander AR; Fehse B
    Blood; 2007 Feb; 109(3):1316-21. PubMed ID: 17018857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
    Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis.
    Bacher U; Asenova S; Badbaran A; Zander AR; Alchalby H; Fehse B; Kröger N; Lange C; Ayuk F
    Clin Exp Med; 2010 Sep; 10(3):205-8. PubMed ID: 19629639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
    Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
    Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
    Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
    Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation.
    Steckel NK; Koldehoff M; Ditschkowski M; Beelen DW; Elmaagacli AH
    Transplantation; 2007 Jun; 83(11):1518-20. PubMed ID: 17565328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
    Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of JAK2
    Latagliata R; Polverelli N; Tieghi A; Palumbo GA; Breccia M; Sabattini E; Villari L; Riminucci M; Valli R; Catani L; Alimena G; Ottaviani E; Fama A; Martinelli G; Perricone M; Spinsanti M; Cavo M; Vianelli N; Palandri F
    Hematol Oncol; 2018 Feb; 36(1):269-275. PubMed ID: 28509339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years.
    Daghia G; Zabelina T; Zeck G; von Pein UM; Christopeit M; Wolschke C; Ayuk F; Kröger N
    Eur J Haematol; 2019 Oct; 103(4):370-378. PubMed ID: 31306511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease.
    Barosi G; Massa M; Campanelli R; Fois G; Catarsi P; Viarengo G; Villani L; Poletto V; Bosoni T; Magrini U; Gale RP; Rosti V
    Leuk Res; 2017 Sep; 60():18-23. PubMed ID: 28622624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation.
    Benjamini O; Koren-Michowitz M; Amariglio N; Kroger N; Nagler A; Shimoni A
    Leukemia; 2008 Oct; 22(10):1961-3. PubMed ID: 18685610
    [No Abstract]   [Full Text] [Related]  

  • 18. Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis.
    Martínez-Trillos A; Maffioli M; Colomer D; Alvarez-Larrán A; Pereira A; Angona A; Bellosillo B; Cervantes F
    Ann Hematol; 2014 May; 93(5):797-802. PubMed ID: 24337516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.
    Ditschkowski M; Elmaagacli AH; Trenschel R; Steckel NK; Koldehoff M; Beelen DW
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1350-1. PubMed ID: 17162218
    [No Abstract]   [Full Text] [Related]  

  • 20. JAK2V617F allele burden is associated with transformation to myelofibrosis.
    Koren-Michowitz M; Landman J; Cohen Y; Rahimi-Levene N; Salomon O; Michael M; Amariglio N; Nagler A
    Leuk Lymphoma; 2012 Nov; 53(11):2210-3. PubMed ID: 22524513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.